sturlimogene erparepvec
AXP000078.1 · Oncolytic virus
- Platform
- HSV-1 (RH018A strain, ICP34.5- ICP47-)
- Originator
- Replimune
- Sponsor
- Replimune
Names
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- RH018A
- Replication
- conditionally replicating
- Modifications
- RL1 (ICP34.5) and US12 (ICP47) deleted
- Transgenes
- CSF2, GALV-GP R-, anti-CTLA-4 antibody
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C176748
- FDA UNII
- 53Z5E7R5KD
Approvals
No regulatory approval recorded.
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07059611 | Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma | Not yet recruiting | Phase 2 | 2027-04-01 | 2027-11-01 | 34 | Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma |
| NCT07218692 | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | Withdrawn | Phase 2 | 2026-08-11 | 2027-08-11 | 0 | Advanced Clear Cell Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Recruiting | Phase 2/3 | 2024-12-17 | 2030-01 | 280 | Metastatic Uveal Melanoma |
| NCT05733598 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Recruiting | Phase 2 | 2024-08-01 | 2027-12-01 | 60 | Biliary Tract Cancer; Hepatocellular Carcinoma |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Terminated | Phase 2 | 2023-06-29 | 2025-08-18 | 5 | MSS; Refractory Metastatic Colorectal Cancer; pMMR |
| NCT04336241 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Active not recruiting | Phase 1 | 2019-10-17 | 2026-10-31 | 36 | Cancer |
Recent changes
No changes recorded in its trials yet.
Notes
RP2: the RP1 backbone with an added anti-CTLA-4 antibody-like molecule. Dosed with and without nivolumab; a phase 2 in colorectal cancer (NCT05733611) was terminated.
How to cite
sturlimogene erparepvec (AXP000078.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000078.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.